Fang Wu, Ph.D.

US Food and Drug Administration

Poster(s):

• (M1130-11-64) Assessing the Impact of Excipient and Food Intake on Bioequivalence Using PBPK and Virtual Bioequivalence Trial: A Case Example with Acyclovir Immediate Release Tablets
  Monday, October 17, 2022

  11:30 AM – 12:30 PM ET

• (M0930-02-07) Using the In Vitro Dissolution Absorption System (IDAS) to Evaluate the Effects of Excipients on the Permeation of Putative Biopharmaceutics Classification System Class III Drugs
  Monday, October 17, 2022

  9:30 AM – 10:30 AM ET

• (W1230-02-08) In Vitro Comparative Dissolution and Permeation Testing Using the In Vitro Dissolution Absorption System (IDAS) for Expanding Biowaivers to Non Q1/Q2 BCS Class III Products
  Wednesday, October 19, 2022

  12:30 PM – 1:30 PM ET